Survival disparities between children, adolescents, and young adults with bone sarcomas are likely multifactorial. Age-dependent differences in the distribution of tumours across anatomical sites and in tumour size appear to play a role. The incidence of and survival from relapse/progression also appear to favour younger patients. Including patients in international, joint paediatric-adult treatment protocols remains a high priority.
Dybdal et al. (Wed,) studied this question.